Induced Pluripotent Stem Cell (iPSC) Global Market Report 2023: Sector to Reach $4.36 Billion by 2027 at a 10.1% CAGR - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

The global induced pluripotent stem cell (ipsc) market will grow from $2.69 billion in 2022 to $2.97 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The induced pluripotent stem cell (ipsc) market is expected to grow to $4.36 billion in 2027 at a CAGR of 10.1%.

North America was the largest region in the induced pluripotent stem cell (iPSC) market in 2022. Western Europe was the second largest region in the induced pluripotent stem cell (iPSC) market. The regions covered in the induced pluripotent stem cell (iPSC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

An increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of the Induced pluripotent stem cell market. Chronic disorders like heart disease, cancer, stroke, diabetes can be treated with Induced pluripotent stem cell. Induced Pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave like embryonic stem cells.

According to the report published by Partnership to Fight Chronic Disorder (PFCD), it was found that out of 133 million Americans, 45% of the population had at least one chronic disorder. Moreover, it was estimated that 7 out of 10 deaths in the USA, which is approximately 1.7 million, are due to chronic disorders and these deaths can be controlled by induced pluripotent stem cell treatment. This rise in incidences of chronic diseases is driving the demand for induced pluripotent stem cell treatment.

The potential risk of tumour is one of the major restraints on the growth of the Induced pluripotent stem cell market. As per a scientific research, it was found that there might be a chance of getting cancer from the treatment and people are unwilling to take treatment through Induced pluripotent stem cell therapy.

According to the report by American Association for cancer research, in most of the cases while doing the experiment it was found that the occurrence of the tumours was prevalent after a short period of time. This risk of developing a tumour due to Induced pluripotent stem cell therapy is limiting the number of patients opting for this treatment, thereby restraining the growth of the market.

Companies in the Induced Pluripotent stem cell market are looking for opportunities for strategic partnerships and collaborations that will help these companies to enter into new geographies and to expand product portfolios. For example, in January 2022, Bristol Myers Squibb and Century Therapeutics entered into a strategic collaboration to develop iPSC-derived allogenic cell therapies for the treatment of acute myeloid leukemia and multiple myeloma. Furthermore, in May 2022, Evotec and Sernova announced strategic partnership to develop iPSC-based beta cell replacement therapy for treatment for type 1 and type 2 diabetes.

National Institute of Health (NIH), a part of Department of Health and Human Services, regulates the market for Induced Pluripotent stem cells (iPSC) in the US. If a company is using, making or planning to acquire iPSCs, they are required to provide some information. For instance, a complete and signed copy of the IPSC checklist must be submitted.

Any acquisitions in the IPSC's must obtain approval from the Institutional review board (IRB), the signed approval documents must be attached to the checklist. If the IPSC lines are purchased from an outside or commercial source these agreement documents must also be attested by the IRB and attached. The IPSC's must be generated by the Intramural Research Program (IRP) under a signed contract before they can be used for any further experimentation.

In August 2021, catalant, a Us-based pharmaceutical company, acquired RheinCell Therapeutics GmbHfor an undisclosed amount. The acquisition will help Catalent to grow in the cell and gene therapy vertical and develop therapies based on induced pluripotent stem cells. RheinCell Therapeutics GmbH is a Germany-based developer of human induced pluripotent stem cells (iPSCs) for next generation cell therapies.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Scope

Markets Covered:

1) By Derived Cell Type: Hepatocytes; Fibroblasts; Keratinocytes; Amniotic Cells; Other Derived Cells

2) By Application: Academic Research; Drug Development And Discovery; Toxicity Screening; Regenerative Medicine

3) By End-User: Hospitals; Research Laboratories

A selection of companies mentioned in this report includes

• Thermo Fisher Scientific Inc.
• FUJIFILM Holdings Corporation (Cellular Dynamics)
• Takara Bio Inc.
• Astellas Pharma Inc.
• Fate Therapeutics
• ViaCyte
• StemCells
• Japan Tissue Engineering Co. Ltd.
• Fate Therapeutics
• Japan Tissue Engineering Co.
• Ncardia
• Axol Bioscience
• ORIG3N
• Lonza
• REPROCELL
• BRISTOL-MYERS SQUIBB (IPIERIAN)
• VIACYTE INC.
• ABM (APPLIED BIOLOGICAL MATERIALS INC.)
• ADDGENE
• ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS INC.
• ALSTEM LLC
• APPLIED STEMCELL INC.
• ATCC
• AXIOGENESIS AG
• AXOL BIOSCIENCEE
• BIO-TECHNE
• BLUEROCK THERAPEUTICS
• GENTARGET INC.
• ID PHARMA CO. LTD.
• INVIVOGEN

For more information about this report visit https://www.researchandmarkets.com/r/udhu97

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900